Performer platform enables users to benchmark clinical trial performance against industry standards, assess key drivers of performance, and provide predictive analytics
CRO Analytics, the leading provider of validated clinical trial performance data, announced that it is seeking sponsor and CRO partners to enroll in a limited Pilot to Production program of the biopharma industry’s first Clinical Trial Quality System (CTQS), Performer™.
Performer is a cloud-based software platform designed to improve clinical research by assessing clinical trial performance through a series of instruments developed over a two-year validation process. The online tools, which take less than five minutes to complete, measure the quality of more than 70 functional areas and professional skills involved in clinical trial delivery. The data is analyzed using a series of algorithms to deliver actionable insights through standard and custom reports to clinical trial teams, functional area leads, and executives.
Since completed assessment data is available immediately, Performer can be used to manage and respond to issues during trial, as well as provide performance analytics at the functional and corporate level. In addition, Performer enhances the value of existing operational and financial metrics by helping users’ better measure the quality associated with those numbers.
Pilot to Production seeks a limited number of sponsor and CRO partners to work over a six-month period with CRO Analytics to develop a deeper understanding of how Performer is used, adds value, and can be improved prior to its full launch next year. Dr. Michael Howley, co-founder and Chief Science Officer (CSO) of CRO Analytics and his team will meet with partners monthly to review the findings.
“This isn’t a product test. In fact, we’ve been using the same application for the past two quarters to collect data in collaboration with Applied Clinical Trials for the first ever industry-wide outsourced clinical trial assessment,” stated Howley, CSO of CRO Analytics and Associate Professor at Drexel University. Dr. Howley, who frequently presents on measuring clinical trial quality at industry conferences added, “Performer offers Pilot to Productionpartners’ immediate insight into their own performance and gives them the ability to benchmark against overall industry performance as well as against the key drivers of performance identified by our validation process.”
“Performer directly addresses many of the on-going frustrations sponsors and service providers experience when trying to evaluate and improve clinical trial performance,” said Peter Malamis, CEO of CRO Analytics. “We are excited about the Pilot to Production program and the opportunity to demonstrate Performer’s very practical and substantial benefits.”
Those interested in participating in Pilot to Production are asked to contact CRO Analytics CEO, Peter Malamis at pmalamis@croanalytics.com.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.